Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
1998-12-03
2004-11-02
Wilson, Michael C. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093210, C514S04400A
Reexamination Certificate
active
06811774
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
Cytokines are molecules (hormones) produced by cells following an antigenic stimulation or an activation by other factors. The first cytokine which will has been produced is interleukin-1 (Il-1). It permits activation of the T cells which, in turn, start producing a whole battery of lymphokines, some of which are essential for the activation of the immune system and the defenses against viral or parasitic infections.
2. Description of Related Art
For some years, cytokines have been used in anticancer immunotherapy. Nevertheless, when they are administered systemically, a number of problems arise. Il-2, for example, produces quite substantial side effects, it is rapidly metabolized, so that high doses have to be administered repeatedly.
Better administration routes which would increase their efficacy while decreasing their adverse effects are hence being sought.
SUMMARY FOR THE INVENTION
The subject of the invention is hence defective recombinant adenoviruses expressing one or more cytokines, as well as the use of these recombinant adenoviruses for making up pharmaceutical compositions, in particular antitumor compositions, more especially compositions which can be injected directly into solid tumors of the host.
The subject of the present invention is defective recombinant adenoviruses, characterized in that they contain a defective, non-replicable adenovirus genome into which one or more nucleic acid sequences coding for one more cytokines, in particular lymphokines, are inserted under the control of one or more promoters capable of being recognised by the polymerases of human cells, more especially of human tumor cells or of cells infiltrating these tumors.
REFERENCES:
patent: 5662896 (1997-09-01), Barber et al.
patent: 6013638 (2000-01-01), Crystal et al.
patent: 6297219 (2001-10-01), Nabel et al.
patent: 0185573 (1986-06-01), None
patent: WO 88/00971 (1988-02-01), None
patent: 2 688 514 (1992-03-01), None
patent: WO 93/19191 (1993-09-01), None
Lebovitz et al., Parvovirus H-1 Expression: Mapping of the Abundant Cytoplasmic Transcripts and Identification of Promoter Sites and Overlapping Transcription Units, May 1986, Journal of Virology, vol. 58 No. 2 pp. 271-280.*
Gu et al.,Parvovirus H-1 Promoter Reguires the trans-Activation Region (tar), and SP1 site, and a TATA Box for Full Activity, 1992, Virology, 187 pp. 10-17.*
Addison, C, et al., “Intranumoral injection of an adenovirus expressing intericulum in 2 induces regression and immunity in a marine breast cancer model”,Proc. Natl. Acad. Sci. USA, 92:8522-8526 (Aug. 1995).
Schmit.Wolf, G. et al., “Cytokines and clinical gene therapy”,Eur. J. Immunol., 25:1137-1140 (1995).
Clark, I. et al., “Roles of TNF in malaria and other parasitic infections”,Imunnology Series, 56:365-407 (1992) Medicine Accession No. 92199019 (Abstract only).
Ovington, K. et al., “Cytokines and immunological control of Elmeria spp.”,International Journal for Parasitology, 25(11):1331-51 (Nov. 1995) Medline Accession No. 96229273 (Abstract only).
Brunda, M. J., “Interleukin-12”,Journal of Leukocyte Biology, 56(2):280-288 (Feb. 1994) Medline Accession No. 94132739 (Abstract only).
Utsunomiya, T. et al., “A relationship between the generation of burn-associated type 2 T cells and their antagonistic cells in thermally injured mice”,Burns, 23(4):281-287 (Jun. 1997) Medline Accession No. 97391891 (Abstract only).
Gluzman et al., Euhágste Vinl Vectors, pp. 187-192 (1982).
Gratham, F.L. et al.,J. Gen. Virol.,36:59-72 (1977).
Quantin et al., “Adenovirus as an Expression Vector in uscle Cells Application to Dystrophin”,Collogue Inserm, (Human Gene Transfer, International Workshop, Paris, France), 219:271-272 (Apr. 11, 1991).
Rosenfeld et al., “Adenovirus-mediated Transfer of a Recombinant Alpha-alntitrypsin Gene to the Lung Epithelium in Vivo”,Science, 252(5004):431-434 (Apr. 19, 1991).
Russell, S.J., “Lymphokine Gene Therapy for Cancer”,Immunology Today, 11(6):196-200 (Jun. 1990).
Stratford-Perricaudet, et al., “Gene Transfer into Animals: The Promise of Adenovirus”,Collogue Inserm, (Human Gene Transfer, International Workshop, Paris, France), 219:51-61 (Apr. 11, 1991).
Venkatesh et al., “Selective Inductiono fToxicity to Human Cells Expressing Human Immunodeficiency Virus Type I Tat by a Conditionally Cytotoxic Adenovirus Vector”,Proceedins of the National Academy of Sciences of USA,87(22):8746-8750 (Nov. 1990).
Winkinson, GWG et al., “Constitutive and Enhanced Expression from the CMV Major IE Promoter in a Defective Adenovirus Vector”,Nucleic Acids Research,20(9):2233-2239 (May 11, 1992).
Graham, F., “Undercurrents: Adenovirus as expression vectors and recombinant vaccines,”Tibtech,8:85-87 (Apr. 1990).
Rosenberg, S. et al., “A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone,”The New England Journal of Medicine, 316(15):889-896 (Apr. 9, 1987).
Singh, S. et al., “Up-Regulation by Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) of Induction of Lymphokine (IL-2)-Activated Killer (LAK) Cells by Human Blood Monocytes,”Int. J. Cancer, 44:170-176 (1989).
Serfling, E. et al.; “Metal-dependent SV40 viruses containing inducible enhancers from the upstream region of metallothionein genes”,IRL Press Limited, Oxford, England,pp. 3851-3859.
Ponta, H. et al., “Hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties,” pp. 1020-1024.
Israel, D. et al., “Highly inducible expression from vectors containing multiple GRE's in CHO cells overexpressing the glucocorticoid receptor,”Nucleic Acids Res.,17(12):4589-4604 (Jun. 26, 1989) (Abstract only).
Wilkinson, G. et al., “Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector”,Nucleic Acids Research, 20(9):2233-2239 (1992).
Colicos, M. et al., “Construction of a recombinant adenovirus containing the denV gene from bacteriophase T4 which can partially restore the DNA repair deficiency in xeroderma pigmentosum fibroblasts”,Carcinogenesis, 12(2):249-255 (Feb. 1991) (Abstract only).
Squiban, P., “France. Transgene Announces Progress in Cancer Clinical Development Programs”,TCLine News, May 14, 2003 (3 pages).
Squiban, P., “Transgene Presents Positive Phase I/II Data on its Adeno-Interferon Gamma Product in Cutaneous Lymphoma at the American Society of Gene Therapy Meeting”,TCLine News, Jun. 11, 2003. (2 pages).
Slos, P. et al., “Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8+ T-cell immunity and NK activity”,Cancer Gene Therapy, vol. 8, No. 5, pp. 321-332 (2001).
Ahmed, C., et al. “In Vivo Tumor Suppression by Adenovirus-Mediated Interferon &agr;2b Gene Delivery”,Human Gene Therapy, vol. 10, pp. 77-84 (Jan. 1, 1999).
Fujii, S., et al. “Activated Dendritic Cells From Bone Marrow Cells of Mice Receiving Cytokine-Expressing Tumor Cells Are Associated With the Enhanced Survival of Mice Bearing Syngeneic Tumors”,Blood, vol. 93, No. 12, pp. 4328-4335 (Jun. 15, 1999).
Miller et al., Targeted vectors for gene therapy, 1995, FASEB, vol. 9, pp. 190-199.*
Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents, vol. 8, pp. 53-69.*
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.*
Crystal, Transfer of genes to humans: Early lessons and obstacles to success, 1995, Science, vol. 270, pp. 404-410.*
Bramson et al.,Direct Intraturmoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That is Associated with Highly Localized Expression of Interleukin-12, Human Gene Therapy 7:1995-2002 (1996).
Cordier et al.,Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene, Gene Therapy, 2:16-21 (1996).
Gambotto et al.,
Haddada Hedi Mohamed
Perricaudet Michel
Ragot Thierry
Centre National de la Recherche Scientifique
Merchant & Gould P.C.
Wilson Michael C.
LandOfFree
Defective recombinant adenoviruses expressing cytokines for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Defective recombinant adenoviruses expressing cytokines for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defective recombinant adenoviruses expressing cytokines for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3303258